# THROMBOSIS UK

**(A Company Limited by Guarantee)**

**REPORT AND FINANCIAL STATEMENTS**

**FOR THE YEAR ENDED 31 JANUARY 2026**

**Registered Charity No: 1090540**

**Company No: 4354472**

L3174 - 26

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

**TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2026**

## REFERENCE AND ADMINISTRATION DETAILS:

### TRUSTEE AND MANAGEMENT

**Trustees**
Andrea Louise Croft (Resigned on 12.09.2025)
Dr Matthew Robert Fay
Professor Ian Maxwell Franklin (Resigned on 19.09.2025)
Simon Hart
Professor Beverley Jane Hunt OBE
Stephane Jaglin
Professor Simon Noble (Resigned 04.09.2025)
Robin Offord
Janet Morgan
Nusaiba Masnurah
Raza Alikhan (Appointed on 01.04.2026)
Fern Guillen (Appointed on 17.03.2026)
Professor Ashley Roger George (Appointed on 01.01.2026)

**CEO**
Jo Jerome, CEO, (Resigned 28.08.2025)
Tiffany Richards, Interim CEO (Appointed on 05.08.2025)

**Secretary**
Professor Beverley Jane Hunt OBE

### REGISTERED OFFICE
Couch Bright King & Co
2 Tolherst Court
Turkey Mill Business Park
Ashford Road
Maidstone
Kent ME14 5SF

### AUDITORS
Couch Bright King & Co
Chartered Accountants
2 Tolherst Court
Turkey Mill Business Park
Ashford Road,
Maidstone
Kent ME14 5SF

### SOLICITORS
Stone King
28 Ely Place
London EC1N 6TD

### BANKERS
National Westminster Bank PLC
Maida Vale
Elgin Avenue
127 Kilburn Road
London NW6 6JL

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

**TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2026**

The Trustees present their annual report and the financial statements for the year ended 31 January 2026.

The financial statements have been prepared in accordance with the accounting policies set out on pages 16 to 17, and comply with the Charities Act 2011, the Statement of Recommended Practice (SORP) applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102), published in October 2019 and the Companies Act 2006.

Thrombosis UK is a charitable company limited by guarantee, incorporated on 16 January 2002 and registered as a charity on 12 February 2002. It has no share capital. Accordingly, the report and financial statements also comply with the requirements of the Companies Act 2006.

## OPENING STATEMENT FROM THROMBOSIS UK CO-CHAIRS

For many years, Thrombosis UK has benefited from the dedication and commitment of a talented team of staff, trustees, volunteers and supporters. This year, however, marked a significant period of change for the charity. Following the departure of our Chief Executive, Jo Jerome, after 11 years of dedicated service, we welcomed a new CEO and several new trustees, while also taking the opportunity to review our future direction and begin developing a new long-term strategy for the organisation. We would like to place on record our sincere thanks for Jo's leadership and contribution over more than a decade, during which she helped strengthen the charity's position as a respected voice in thrombosis awareness, education and patient support.

Periods of transition can bring uncertainty, but they also create opportunities to reflect, adapt and grow. We are proud that, despite major changes, the charity and its supporters have continued to demonstrate commitment, resilience and an unwavering focus on our mission. Thanks to their efforts, Thrombosis UK has continued to deliver a wide range of high-quality activities that support patients, educate healthcare professionals and raise awareness of thrombosis across the UK.

Among the highlights of the year was the success of National Thrombosis Week 2025, which brought together patients, healthcare professionals and researchers through our flagship virtual conference. We were also proud to celebrate innovation and excellence through the VTE Awards at the Houses of Parliament, recognising individuals and organisations working to improve thrombosis prevention, care and patient outcomes. Our partnerships with NHS organisations, healthcare providers, researchers and academic institutions have continued to grow, helping us extend our reach and influence. A particular milestone was the launch of the Early Pregnancy Blood Clot Risk Assessment Questionnaire, developed alongside NHS England and clinical experts to help identify women at increased risk of thrombosis earlier in pregnancy. As a result of the DIRECT study, which highlighted the key role of GPs in VTE diagnosis, we are now working on a "Think VTE" tool to identify very high-risk patients in GP records.

As we look to the year ahead, there is much to be proud of and much still to do. Thrombosis remains a significant cause of death and disability, and the need for greater awareness, prevention and earlier diagnosis remains as important as ever. Our focus will be on building a sustainable future for the charity, strengthening partnerships, increasing our impact and ensuring that the voices of patients continue to shape our work. We would like to close with heartfelt thanks to our fellow Trustees, employees, volunteers, supporters, healthcare partners and funders. Your dedication, expertise and generosity make our work possible, and together we can continue to reduce the impact of thrombosis and improve outcomes for people and families across the UK

**J Morgan & B Hunt**
Co-Chairs, Thrombosis UK

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

**TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2026**

## OBJECTIVES AND STRATEGIES

Thrombosis UK was established to advance medical science in relation to the diagnosis, causes, prevention, alleviation, management, and cure of thrombosis and for the promotion of knowledge and public education of the understanding and awareness of thrombosis. Using the powers conferred by the Memorandum of Association, Thrombosis UK aims to fund:

- A range of studies looking at why and how thrombosis occurs.
- Research into the management and the improvement of current treatments available.
- An education programme that informs people about the causes, effects, prevention, and recommended management of thrombosis.
- Provide a network of support for those affected by thrombosis.

## ORGANISATION AND STRUCTURE

The Board of Trustees, who are also Directors of the company, govern Thrombosis UK.

The Trustees have the power to appoint, and remove any member, any member to act as Secretary to the Charity and all vote on the appointment of the Chair, Treasurer, and other Honorary Officers.

The charity seeks to ensure Trustees are appointed to fulfil the changing and on-going needs of the charity's activities and outcomes. A Trustee job description is agreed when vacancies become available to ensure existing and new Trustees have clarity on their roles and they each bring skills that complement and benefit Thrombosis UK.
New Trustees are appointed with the unanimous approval of existing Trustees. All Trustees give freely of their time and expertise and receive no remuneration for their work.

The day-to-day administration of the Charity is the responsibility of the Chief Executive Officer employed on a 0.8 permanent FTE contract. An Interim CEO was in post from 5 August 2025 and was subsequently made permanent with effect from 4th November 2025.

A new Fundraising & Communications Officer was employed from 10th December 2025 on a 0.6 permanent contract. A new Community Engagement Officer was employed from 2nd December 2025, also on a 0.6 permanent contract.

In December 2025, the board of Trustees reviewed the 0.5 contract of the Clinical Psychologist and decided not to extend it. The REGAIN project effectively closed on 31st January 2026.

The role of the temporary 0.4 Consultant as Operations Lead came to an end on 31st May 2025.

## AIMS AND ACTIVITIES

The Charity aims to promote greater awareness and understanding of venous thromboembolism (VTE) to improve:

- Prevention of avoidable blood clots.
- Timely detection and prompt diagnosis of VTE.
- Appropriate management that improves patient outcomes.
- Timely support and education to enable patients to restore their well-being and health.

To support achievement of this, the Charity concentrates on three key areas.

- Awareness
- Education
- Research

## AWARENESS AND EDUCATION

Raising awareness remains a key objective of the charity's work, encompassing both specific awareness activities and creating opportunities through linked initiatives. The team attended the inaugural national networking event "VTE Together" in October 2025, with a presentation given by REGAIN's clinical psychologist on "Life after PE – Recovery and Survivorship". In addition, the Community Engagement Officer delivered an online awareness raising presentation to vascular science students at Gloucestershire University.

Thrombosis UK is committed to advancing education and understanding of venous thromboembolism (VTE) among patients, healthcare providers, and the public. During National Thrombosis Week 2025 (NTW'25) the charity delivered its flagship virtual Conference on 6 May 2025, bringing together healthcare professionals, patients, carers and leading experts from across the UK and around the world to share knowledge, showcase research and discuss developments in thrombosis prevention and management. The free event played a vital role in supporting education, encouraging collaboration and helping to translate best practice into improved patient care. The conference featured 16 sessions, secured 10 CPD credits from the Royal College of Pathologists and attracted 2,868 registrations. While primarily UK-based, delegates joined from 13 countries. The programme included webinars, interactive round table discussions, poster exhibitions and oral presentations, creating opportunities for learning and professional exchange. Feedback from delegates identified the relevance of the agenda, easy access to live and on-demand content, and CPD accreditation as the main reasons for attending the conference.

On 13th May 2025 the charity organised the VTE awards, hosted by Sarah Green MP, at the Terrace Pavilion, Houses of Parliament. The event brought together healthcare professionals from across the UK to celebrate excellence and innovation in thrombosis prevention, diagnosis and care. The awards recognised individuals and teams who have developed effective, sustainable approaches that improve patient outcomes and raise standards of care. Examples included the "Award for Work in VTE Prevention", won by Bronglais General Hospital, and the "Enhancing Patient Experience Award", which recognised initiatives focused on improving support, information and follow-up for patients. The awards are an important part of the charity's work, highlighting best practice, encouraging learning across organisations and promoting greater awareness of thrombosis and its impact. They also provide an opportunity to recognise the commitment of those working to improve patient care while fostering collaboration across the sector, helping to drive improvements in care and outcomes for patients across the UK.

For World Thrombosis Day 13th October 2025, the charity hosted a CPD-accredited symposium focused on advancing thromboprophylaxis research and improving patient outcomes. Chaired by Prof Beverley Hunt OBE, the programme brought together leading experts to present the latest evidence and innovations in VTE prevention. Topics included compression stocking trials, reducing VTE risk following hip fractures through the DIRECT Trial, thromboprophylaxis for lower limb immobilisation, prevention strategies during the first trimester of pregnancy, and the DETECT-VTE initiative. The event provided healthcare professionals with valuable insights into emerging research, best practice, and future developments in thrombosis prevention.

Thrombosis UK was successful in securing support from NHS Scotland to include the 'Healthier Scotland' logo on key awareness and information materials. It was also agreed that they would advertise our accredited conferences across their NHS education network and host films of our accredited sessions on their platform for staff training.

In January 2026 Thrombosis UK launched the "Early Pregnancy Blood Clot Risk Assessment Questionnaire", which it had developed with NHS England and national experts. This was in response to the MBRRACE report which showed that in 2021-23 VTE was the leading cause of maternal morbidity and mortality in the UK, accounting for 16% of maternal deaths.

NHS England's 2026 Maternal Care Bundle recommends offering this questionnaire at the first NHS contact following a positive pregnancy test, before the first antenatal booking appointment. It is designed to identify women with the highest-risk factors so that urgent clinical assessment and preventative treatment can follow.

## SUPPORT & COMMUNITY ENGAGEMENT

During NTW'25 the charity delivered its Let's Talk Clots campaign, encouraging people to speak openly about thrombosis and increase awareness of the risks, signs and symptoms of blood clots. The campaign combined social media, educational resources and personal stories to reach both the public and healthcare professionals. There were 2,837 new downloads during the year, with the most visited pages being "Signs and Symptoms", "Risk Factors" and "How to reduce my risks".

By 31st January 2026 there were a total of 2,662 members of the charity's closed Facebook group. It had been without moderation for some time and some posts included concerns about some of the changes at the charity, for example, the closing of the REGAIN project. However, increased engagement and reassurance, together with a new moderator and updated guidelines, has led to a generally positive, larger online community.

Thrombosis UK's REGAIN project initially intended to provide free, online access to one to one clinical psychological support for individuals diagnosed with Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT), but who were unable to access local psychological support. As the demand for VITT specific support progressively declined from 2023, the project had shifted into providing general one to one support for a relatively small number of clients. Whilst this support was undoubtedly invaluable, demand way outstripped supply to the point where Thrombosis UK could not promote the project. In December 2025 the board evaluated the support delivery model and decided that the impact of REGAIN was, and would remain, limited as it was unscalable. They decided not to extend the project contract beyond 31st January 2026. To ensuring patients weren't left without support, Thrombosis UK dovetailed the winding down of REGAIN with a series of new drop-in groups, based on a peer support model. The new peer support sessions began with an introductory online meeting, facilitated by the Community Engagement Officer, which was attended by 16 people. Participants were encouraged to give feedback on their preferred format and frequency, and which topics they'd like to explore. There was strong interest for 'General' and 'Newly Diagnosed' groups, plus topics relating to Young People; Pregnancy and Post Thrombotic syndrome. These has been incredibly well received and are able to support much larger numbers on a regular basis.

## RESEARCH

The charity's involvement in research studies has increased with regular requests to secure 'Patient and Public Involvement' (PPI) which included:

- Convening and facilitating patient focus group (as well as being co-applicant) for HASTE - Hip Replacement Blood Thinners Study, Queen Mary's.
- Distributing and promoting patient survey for national VTE prevention trial for prophylaxis in day case surgery DOAC, Addenbrooke's.
- Convening and facilitating focus group for Early Pregnancy Risk Assessment Tool, for inclusion in NHS Maternal Bundle.
- Gathering feedback from participants on their final study design for FLOW study (Focusing on LOWering blood loss in anticoagulated women with heavy menstrual bleeding), HaemTrial.

During 2025 the Detect VTE project, a collaboration between Thrombosis UK, GTD Healthcare and Oberoi Consulting, entered its second phase. The aim was to develop an integrated clinical system tool which required no external software or patient data transfer. The project team further refined the alert criteria to improve identification of higher-risk patients, which included revising the structured consultation templates, as well as planning the role out and testing across the GTD Healthcare network.

## INTERNAL

The overarching theme of this year has been transition. There have been significant changes to the board but the most keenly felt was the decision of Thrombosis UK's longstanding CEO, Jo Jerome, to move on to pastures new. Having spent 11 years with the charity, Jo's wealth of knowledge and compassion for those affected by VTE gained her huge respect amongst both the medical and lay communities. The board of Trustees have taken this opportunity to review and reset with work on a new strategic plan underway. On an operational level, a new CEO took over the running of the charity, prioritising the recruitment of a new team, to ensuring the charity returned to capacity after the brief hiatus in service.

## FUNDRAISING & COMMUNICATIONS

Supporters took part in a wide variety of fundraising events across the UK over the past year. We were delighted to welcome both new supporters and returning fundraisers and donors who continue to champion the work of Thrombosis UK.

Over the last 12 months, supporters participated in more than 81 unique fundraising events, demonstrating extraordinary commitment, enthusiasm, and generosity. This remarkable achievement is a testament to the dedication of everyone who has chosen to support Thrombosis UK and help raise awareness of thrombosis and venous thromboembolism.
Among the many incredible fundraising efforts, Ian McClean raised an outstanding £3,774.47 through the London to Paris Bike Ride. Liam Corley raised £2,957 by taking part in the Yorkshire Marathon, while Emily Scoones raised £2,880 through the Richmond RunFest Marathon. Adam Lister also made a significant contribution, raising £1,874.03 in the London Marathon. Their dedication and determination, alongside that of all our fundraisers, has made a meaningful impact on the work of Thrombosis UK by raising an impressive £87,542.61. We were also extremely lucky to receive a very generous legacy of £20,457.62 from William Dodds.

The breadth of fundraising activities highlights the diverse ways supporters choose to get involved. Events included marathons, 10K and 5K runs, walks, treks, swimming challenges, and cycling events. Endurance events, particularly marathons and organised runs, continue to be especially popular and generate substantial fundraising income, while walks, treks, swims, and cycling challenges also make valuable contributions. Maintaining a diverse range of fundraising opportunities helps appeal to different supporters and encourages wider participation throughout the year.
Thrombosis UK is immensely grateful to everyone who fundraises and donates in support of our mission. Sadly, many people are motivated to support the charity following their own experience of thrombosis or after the loss of a loved one. We would like to sincerely thank all our supporters and reiterate that their fundraising makes a real difference. Their efforts help us raise awareness, improve understanding of thrombosis and VTE, and provide support and information to those affected.

The charity continued to work on improving the user journey by making the overall website more navigable. Work was also undertaken to simplify the layout of the fundraising offering, making event selection and registration more comprehensive. The charity developed a strong brand identity for its social media posts. It also developed a planned schedule, using different themes and timings, to maximise impact across all channels.

## FINANCIAL REVIEW

During the year ended 31 January 2026, the charity recorded a deficit of £124,240 (2025: deficit of £79,213). Total incoming resources decreased by approximately 30% compared with the prior year, while expenditure decreased by almost 12%.

The significant reduction in incoming resources was primarily due to donated services received from Costello Medical in the prior year, which were not received in the current year. In addition, Thrombosis UK did not receive sponsorship fees from events associated with National Thrombosis Week (NTW) and World Thrombosis Day (WTD) during the year ended 31 January 2026 (see Note 4 on page 17).

The continuing economic and political uncertainty has affected the charity's ability to forecast corporate and individual funding commitments with confidence. As in the previous year, the charity's budget was prepared on the basis that its planned charitable activities would be funded from income raised during the year. However, the Trustees recognised that it might be necessary to utilise a proportion of the charity's general unrestricted reserves to support the delivery of these activities.

The charity's net assets decreased from £588,007 at 31 January 2025 to £463,767 at 31 January 2026. The Trustees consider that the level of net assets remains consistent with the charity's reserves policy. General unrestricted funds recorded a small deficit of £7,550 for the year.

Further details of the charity's financial performance are set out in the Statement of Financial Activities on page 13.

## PLANS FOR THE FUTURE

Over the next three years, Thrombosis UK will focus on high-impact, scalable activity rather than direct service provision. It will achieve this by, raising awareness at national and targeted levels, supporting healthcare improvement and prevention, influencing policy and system priorities and working in partnership to maximise reach and impact. It will prioritise people at risk of thrombosis, healthcare professionals driving prevention and policy-makers shaping national priorities. This model allows the charity to deliver system-wide change with relatively modest investment.

1. Increasing Awareness and Support:
   - Deliver national and targeted awareness campaigns.
   - Provide high-quality, trusted information.
   - Improve access to support through signposting and peer-led approaches.

2. Strengthening Prevention and Care:
   - Support best practice in thrombosis prevention.
   - Focus on areas for greatest impact areas (such as pregnancy and women's health).
   - Work closely with clinicians and healthcare systems to effect change.

3. Influencing Policy and Systems:
   - Advocate for thrombosis training, management and audit as a priority within the NHS
   - Contribute to/advocate for national policy and guidance
   - Build partnerships to drive system-level change

4. Building a Sustainable Organisation:
   - Grow and diversify funding.
   - Strengthen governance and delivery capacity.
   - Focus resources on the highest-impact opportunities.

5. Long-term success:
   - Significantly increase awareness of thrombosis across key populations (current focus, women during pregnancy and birth, psychiatric patients, missed diagnosis opportunities).
   - Greater use of trusted information, improving patient understanding and decision-making.
   - Stronger adoption of prevention practices, particularly in maternity and high-risk settings.
   - Greater influence on policy and healthcare priorities.

## REFERENCE AND ADMINISTRATION DETAILS

A Board of ten Trustees, who are also Directors of the company, govern Thrombosis UK. The Trustees have the power to appoint and remove any member to act as Secretary to the charity and all - vote on the appointment of the Chairman, Treasurer, and other Honorary Officers. The charity seeks to ensure Trustees are appointed to fulfil the changing and on-going needs of the charity's activities and outcomes. New Trustees are appointed with the unanimous approval of existing trustees.

All Trustees give freely of their time and expertise and receive no remuneration for their work as Trustees. The current list of Trustees, who acted throughout the period of review, is given on page 1.

Trustees' meetings are held a minimum of twice per year. Email correspondence is used to keep Trustees updated in between meetings and the CEO meets with Thrombosis UK's Medical Leads and /or Chair of Trustees between four-six times per year to discuss projects and agreed strategic and directional development. The PAC (Professional Advisory Committee) meet on a quarterly basis and during the year and during this period discussed strengthening governance, shaping future strategy, enhancing patient and public involvement, and expanding education and awareness activities.

## TRUSTEES' RESPONSIBILITIES IN RELATION TO THE FINANCIAL STATEMENTS

The trustees (who are also directors of Thrombosis UK for the purposes of company law) are responsible for preparing the Trustees' Report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year, which give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for the year.

In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities Statement of Recommended Practice (SORP).
- Make judgements and estimates that are reasonable and prudent.
- Prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

The Trustees are responsible for keeping proper accounting records that disclose with reasonable accuracy at any time the financial position of the charitable company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the charitable company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In accordance with company law, the Trustees certify that:

- so far as we are aware, there is no relevant audit information of which the company's auditors are unaware; and
- as Trustees we have taken all the steps that we ought to have taken in order to make ourselves aware of any relevant audit information and to establish that the company's auditors are aware of that information.

The Trustees are responsible for the maintenance and integrity of the corporate and financial information included on the charitable company's website. Legislation in the United Kingdom governing the preparation and dissemination of financial statements may differ from legislation in other jurisdictions.

## AUDITORS

The Auditors, Messrs Couch Bright King & Co., have expressed their willingness to continue in office and a resolution proposing their re-appointment will be put to the Trustees at the forthcoming Annual General Meeting.

## SMALL COMPANY EXEMPTION

This report has been prepared in accordance with the provisions applicable to companies entitled to the small companies' exemption.

## RESERVES POLICY

In the course of the development of the charity we will take account of the need to have reserves, and a policy, to honour future funding commitments that we make. We will also ensure that funds are sufficient to cover one year's charitable activity plus sufficient funds to cover all operating costs of the charity.

## RISK ASSESSMENT

We consider the systems we have in place for the day-to-day operation of Thrombosis UK to be appropriate to our current size of operation, but we are aware that as we grow, we will need to develop and implement procedures and reporting regimes to mitigate the risks associated with running a charitable company.

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No.: 4354472**

## TRUSTEES' ANNUAL REPORT FOR THE YEAR ENDED 31 JANUARY 2026

### PUBLIC BENEFIT

The Trustees confirm, to the best of their knowledge and belief, that they have complied with Section 4 of The Charities Act 2011 in respect of having due regard to Public Benefit Guidance published by the Charity Commission.

Approved by the Trustees on: 9th October 2026

Janet Morgan
Janet Morgan (Oct 9, 2026 19:42:55 GMT+1)

**Janet Morgan**
Co-Chair

## INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THROMBOSIS UK
**Registered Charity No: 1090540**

### Opinion

We have audited the financial statements of Thrombosis UK for the year ended 31st January 2026 which comprise the primary statements such as the Statement of Financial Activities including Income and Expenditure Account, the Balance Sheet, the Statement of Cash flows and the related notes. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Generally Accepted Accounting Practice including FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the charitable company's affairs as at 31st January 2026 and of its incoming resources and application of resources; including its income and expenditure, for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice applicable to smaller entities;
- have been prepared in accordance with the requirements of the Companies Act 2006.

### Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditor's responsibilities for the audit of the financial statements section of our report. We are independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, including the FRC's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

### Conclusions relating to going concern

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

### Other information

The other information comprises the information included in the Trustees Annual Report, other than the financial statements and our auditor's report thereon. The trustees are responsible for the other information contained within the annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

**Opinions on other matters prescribed by the Companies Act 2006**

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report (incorporating the Directors' Report) for the financial year for which the financial statements are prepared is consistent with the financial statements; and
- the Trustees' Report has been prepared in accordance with applicable legal requirements.

**Matters on which we are required to report by exception**

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report.

We have nothing to report in respect of the following matters in relation to which the Companies Act 2006 requires us to report to you if, in our opinion:

- adequate accounting records have not been kept, or returns adequate for our audit have not been received from branches not visited by us; or
- the financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit; or
- the Trustees were not entitled to prepare the financial statements in accordance with the small companies' regime and take advantage of the small companies' exemptions in preparing the Directors' Report and from the requirement to prepare a Strategic Report.

**Responsibilities of trustees**

As explained more fully in the Trustees' Responsibilities Statement set out on page 8, the Trustees (who are also the directors of the charitable company for the purposes of the company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

**Auditor's responsibilities for the audit of the financial statements**

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

**Auditor's responsibilities for the audit of the financial statements (.....Continued)**

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The specific procedures for this engagement and the extent to which these are capable of detecting irregularities, including fraud is detailed below:

We have;

- Obtained an understanding of the legal and regulatory framework applicable to the entity and how the entity is complying with that framework;
- Obtained an understanding of the entity's policies and procedures on compliance with laws and regulations, including documentation of any instances of non-compliance;
- Identified the laws and regulations that have significance in the context of the entity;
- Obtained an understanding of the entity's risk assessment process, including the risk of fraud;
- Assessed and evaluated the susceptibility of the entity's financial statements to material misstatement, through error and fraud;
- Implemented procedures to enable the identification and testing of unusual or unexpected journal entries;
- Evaluated the assumptions and judgements used by management within significant accounting estimates and assessed if these indicate evidence of management bias;
- Tested significant transactions, in particular the evaluation of the business rationale for any which appear unusual or outside the company's normal course of business;
- Reviewed the financial statements and tested the disclosures against supporting documentation;
- Communicated relevant matters (including those above) to all members of the audit team to ensure they understood the risks specific to the entity and the audit procedures planned to mitigate these.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditor's report.

**Use of our report**

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an auditor's report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members as a body, for our audit work, for this report, or for the opinions we have formed.

Ms Tarwa Mohammed BA FCA (Senior Statutory Auditor)
For and on behalf of
Couch Bright King & Co
Chartered Accountants &
Statutory Auditors

2 Tolherst Court
Turkey Mill Business Park
Ashford Road, Maidstone
Kent ME14 5SF

**12th October 2026**

**THROMBOSIS UK**

**Registered Charity No: 10905401**
**Company No: 4354472**

## STATEMENT OF FINANCIAL ACTIVITIES
## (Including Income and Expenditure Account)
## FOR THE YEAR ENDED 31 JANUARY 2026

| | Notes | Unrestricted General Funds £ | Unrestricted Designated Funds £ | Restricted Funds £ | Year to 31.01.2026 Total Funds £ | Year to 31.01.2025 Total Funds £ |
|---|---|---|---|---|---|---|
| **Income:** | | | | | | |
| Donations, legacies and gifts | 3 | 180,854 | - | 666 | 181,520 | 249,019 |
| *Income from Charitable activities;* | 4 | | | | | |
| Educational meetings | | - | - | - | - | 970 |
| Events - Sponsorship | | - | - | - | - | 20,356 |
| *Income from other trading activities;* | 5 | | | | | |
| Awareness Literature | | 220 | - | - | 220 | 337 |
| *Investment Income* | | | | | | |
| Bank Interest | | 22,080 | - | - | 22,080 | 22,544 |
| **Total income** | | 203,154 | - | 666 | 203,820 | 293,226 |
| **Expenditure** | | | | | | |
| Costs of raising funds | 6 | 4,475 | - | - | 4,475 | 4,908 |
| Costs of charitable activities | 7 | 206,229 | - | 117,356 | 323,585 | 367,531 |
| **Total Expenditure** | | 210,704 | - | 117,356 | 328,060 | 372,439 |
| **Net income and Net movements in funds** | | (7,550) | - | (116,690) | (124,240) | (79,213) |
| **Transfers** | | - | - | - | - | - |
| Net movements in funds | | (7,550) | - | (116,690) | (124,240) | (79,213) |
| **Reconciliation of funds** | | | | | | |
| Total funds At 1 February 2025 | | 380,082 | - | 207,925 | 588,007 | 667,220 |
| Total Funds At 31 January 2026 | 14 | 372,532 | - | 91,235 | 463,767 | 588,007 |

The statement of financial activities includes all gains and losses recognised in the year.
All income and expenditure derive from continuing activities.

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

## BALANCE SHEET
## AS AT 31 JANUARY 2026

| | Notes | 2026 £ | 2025 £ |
|---|---|---|---|
| **Fixed Assets** | | | |
| Tangible fixed assets | 10 | - | - |
| **Current Assets** | | | |
| Debtors | 12 | 2,025 | 17,312 |
| Cash at bank and in hand | | 549,091 | 586,045 |
| | | 551,116 | 603,357 |
| **Creditors (amounts falling due within one year)** | 13 | 87,349 | 15,350 |
| **Net Current Assets** | | 463,767 | 588,007 |
| **Net Assets** | | 463,767 | 588,007 |
| **Represented by:** | | | |
| **Restricted funds** | 14 | 91,235 | 207,925 |
| **Designated Funds** | 14 | - | - |
| **Unrestricted funds** | | | |
| General funds | 14 | 372,532 | 380,082 |
| **Total unrestricted funds** | | 463,767 | 588,007 |
| **Total funds** | | 463,767 | 588,007 |

The accounts have been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by the Trustees on **9th October 2026**

Signed on their behalf by

Simon Hart (Oct 9, 2026 15:51:16 EDT)

**Simon Hart**
Trustee

Janet Morgan (Oct 9, 2026 19:42:55 GMT+1)

**Janet Morgan**
Co-Chair

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

## STATEMENT OF CASH FLOWS
## FOR THE YEAR ENDED 31 JANUARY 2026

| | Note | 2026<br>£ | 2025<br>£ |
|---|---|---|---|
| **Cash flows from operating activities:** | | | |
| Net movements in funds for the year | | (124,240) | (79,213) |
| | | (124,240) | (79,213) |
| Movements in working capital | | | |
| Dividends and interest from investments | | (22,080) | (22,544) |
| Decrease/(Increase) in Debtors | | 15,287 | 4,715 |
| (Decrease)/Increase in Creditors | | 71,999 | (7,031) |
| Net cash generated by operating activities | | (59,034) | (104,073) |
| **Cash flows from investing activities:** | | | |
| Dividends and interest from investments | | 22,080 | 22,544 |
| Cash used in investing activities | | 22,080 | 22,544 |
| Increase in cash and cash equivalents | | (36,954) | (81,529) |
| Cash and cash equivalents at beginning of the year | | 586,045 | 667,574 |
| Cash and cash equivalents at the end of the year | 11 | 549,091 | 586,045 |

**THROMBOSIS UK**

**Registered Charity No: 1090540**
**Company No: 4354472**

**NOTES TO THE ACCOUNTS**
**FOR THE YEAR ENDED 31 JANUARY 2026**

**1) Statutory Information**

a) **Company Status**

The charity is a company limited by guarantee, incorporated in England and Wales. The registered office is 2 Tolherst Court, Turkey Mill Business Park, Ashford Road, Maidstone, Kent ME14 5SF. The principal office address is PO Box 1242, Chew Magna, Bristol, BS40 8WG.

The members of the company are the trustees named on page 1. In the event of the charity being wound up, the liability in respect of the guarantee is limited to £1 per member of the charity.

b) **Charitable Status**

Thrombosis UK is a registered charity, registration number 1090540 and in consequence is exempt from taxation on income arising from and expended on its charitable activities.

**2) Accounting Policies**

The principal accounting policies, all of which have been applied consistently throughout the year, are set out below:

a) **Basis of Preparation**

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland issued in October 2019, the Financial Reporting Standard applicable in the United Kingdom and Republic of Ireland (FRS 102), the Charities Act 2011, the Companies Act 2006 and UK Generally Accepted Accounting Practice.

Thrombosis UK meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

b) **Functional and presentation currency**

The company's functional and presentation currency is GBP.

c) **Going Concern**

The Trustees continue to adopt the going concern basis in preparing the financial statements and confirm there are no material uncertainties about the charity's ability to continue as a going concern.

d) **Fixed Assets and Depreciation**

Depreciation is charged on a straight-line basis, in order to write off the assets over their useful economic lives as follows:
Computer and Other Equipment over 3 years
Assets acquired under a value of £1,500 are charged to the Statement of Financial Activities in the year of acquisition.

e) **Income and Expenditure recognition**

Income is recognised when the charity has entitlement to the funds, any performance conditions attached to the items of income have been met, it is probable that the income will be received, and the amount can be measured reliably. Income is deferred to match the period of the terms of the grant documentation or terms of agreement where applicable.

The Charity, in common with many others of a similar size and organisation, derives a substantial proportion of its income from voluntary donations. Such donations are recognised and entered into the accounting records when they are received. Other income, such as bank interest, is accounted for on an accruals basis.

On receipt, donated services are recognised on the basis of the value of the gift to the Charity which is the amount the Charity would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

All expenditure is accounted for on accruals basis.

f) **Debtors and creditors receivable / payable within one year**
Debtors and creditors with no stated interest rate and receivable or payable within one year are recorded at transaction price. Any losses arising from impairment are recognised in expenditure.

g) **Unrestricted Fund**
Unrestricted funds are donations, gifts and other incoming resources receivable or generated for the objects of the charity without further specified purpose and are available as general funds or for purposes as designated and agreed by all the Trustees.

h) **Designated Fund**
Designated funds (where applicable) are unrestricted funds earmarked by the Trustees for particular purposes.

i) **Restricted Fund**
Restricted funds are donations, gifts and other incoming resources receivable or are generated for the objects of the charity with a specified purpose. They can only be used in accordance with the donor's wish or by the terms of a public appeal.

| | | 2026 | 2025 |
|---|---|---|---|
| | | £ | £ |
| 3) | **Donations and gifts** | | |
| | Restricted | | |
| | Research | 666 | - |
| | Unrestricted | | |
| | Donations | 165,701 | 158,785 |
| | Gift Aid | 15,153 | 14,046 |
| | Donated Services * | - | 76,188 |
| | | 181,520 | 249,019 |

The number of general donations we have received during the year has seen a small increase compared to prior year. Thrombosis UK is immensely grateful to all of those who have organised a fundraising event for the charity.

* Donated services comprise pro bono support received from Costello Medical, who provided research data analysis for the Detect VTE audit, and from Curious Health, who contributed communication and PR services in support of our awareness campaign.

| | | 2026 | 2025 |
|---|---|---|---|
| | | £ | £ |
| 4) | **Income from charitable activities** | | |
| | Educational Meetings | - | 970 |
| | Events - Sponsorship | - | 20,356 |
| | | - | 21,326 |
| 5) | **Income from other trading activities** | | |
| | Awareness Literature | 220 | 337 |
| | | 220 | 337 |

**6) Costs of raising funds**

| | | |
|---|---|---|
| Donations | 562 | 1,993 |
| Events | 3,913 | 2,915 |
| | 4,475 | 4,908 |

**7) Analysis of costs of charitable activities**

| | Restricted | Designated / Unrestricted | 2026 | 2025 |
|---|---|---|---|---|
| | £ | £ | £ | £ |
| Research Grant / Detect VTE Audit Study | 110,899 | - | 110,899 | 54,207 |
| Travel Fellowship Grants | - | - | - | 12,100 |
| VTE Grand Appeal | 3,143 | 4,016 | 7,159 | - |
| Awareness Resources | 3,314 | 32,367 | 35,681 | 39,612 |
| Awareness Literature | - | 5,880 | 5,879 | 12,929 |
| Thrombosis Education | - | 300 | 300 | 345 |
| Donated Services (Note 3) | - | - | - | 76,188 |
| Website & App Costs | - | 17,028 | 17,028 | 11,059 |
| Support Costs (Note 8) | - | 123,459 | 123,459 | 152,426 |
| Governance Costs (Note 8) | - | 23,179 | 23,179 | 8,665 |
| **Total** | 117,356 | 206,229 | 323,585 | 367,531 |

**8) Analysis of Support and Governance costs**

Thrombosis UK initially identifies its support costs which relate to the governance function and then the remaining support costs are apportioned as follows;

| | General Support £ | Governance Function £ | Total 2026 £ | Basis of apportionment |
|---|---|---|---|---|
| Trustee and other business meetings | - | 804 | 804 | Invoiced events |
| Salaries, wages and related costs | 104,263 | - | 104,263 | Allocated on time |
| General Office | 13,840 | - | 13,840 | Invoiced events |
| Audit fees | - | 6,930 | 6,930 | Governance |
| Consultancy Fees | - | 12,250 | 12,250 | Governance |
| Legal and other professional fees | 5,356 | 3,195 | 8,551 | Governance |
| | 123,459 | 23,179 | 146,638 | |

**Analysis of Support and Governance costs (.....Continued)**

| | General Support £ | Governance Function £ | Total 2025 £ | Basis of apportionment |
|---|---|---|---|---|
| Trustee and other business meetings | - | 274 | 274 | Invoiced events |
| Salaries, wages and related costs | 121,888 | - | 121,888 | Allocated on time |
| General Office | 13,401 | - | 13,401 | Invoiced events |
| Audit fees | - | 6,930 | 6,930 | Governance |
| Consultancy Fees | 13,104 | - | 13,104 | Governance |
| Legal and other professional fees | 4,033 | 1,461 | 5,494 | Governance |
| | 152,426 | 8,665 | 161,091 | |

**9) Staff costs**

| | 2026 £ | 2025 £ |
|---|---|---|
| Salaries | 99,214 | 110,682 |
| Employers National Insurance | 1,542 | 5,374 |
| Pensions | 3,507 | 5,832 |
| | 104,263 | 121,888 |
| The average number employed during the year was | 3 | 4 |

There are no employees with emoluments above £60,000.
The Key Management Personnel of the charity comprise the Trustees and the Chief Executive Officer. The Trustees have not received any remuneration for their work as Trustees. The total employee benefits of the Key Management Personnel were £57,457 (2025: £49,720).

**10) Fixed Assets**

| | Computer Equipment £ | Total £ |
|---|---|---|
| **Cost** | | |
| At 1st February 2025 | 4,697 | 4,697 |
| Additions | - | - |
| | 4,697 | 4,697 |
| **Depreciation** | | |
| At 1st February 2025 | 4,697 | 4,697 |
| Charge for year | - | - |
| | 4,697 | 4,697 |
| Net Book Value 31st January 2025 | - | - |
| Net Book Value 31st January 2026 | - | - |

## NOTES TO THE ACCOUNTS
## FOR THE YEAR ENDED 31 JANUARY 2026

| | | 2026 | 2025 |
|---|---|---|---|
| | | £ | £ |
| **11)** | **Cash and cash equivalents** | | |
| | Cash at Bank | 549,091 | 586,045 |
| **12)** | **Debtors** | | |
| | Gift Aid | 107 | 470 |
| | Prepayments & Accrued Income | 1,918 | 16,842 |
| | | 2,025 | 17,312 |
| **13)** | **Creditors: Amounts falling due within one year** | | |
| | Other taxes | 3,218 | 2,360 |
| | Grants Payable | - | 2,900 |
| | Other creditor & Accruals | 84,131 | 10,090 |
| | | 87,349 | 15,350 |

**14) Movement in Funds**

| | At 1st February 2025 | Incoming Resources | Outgoing Resources | Transfers | At 31st January 2026 |
|---|---|---|---|---|---|
| | £ | £ | £ | £ | £ |
| **Restricted funds:** | | | | | |
| Research | 6,459 | 666 | - | - | 7,125 |
| REGAIN Programme | - | - | - | - | - |
| VTE Grand Appeal | 3,143 | - | 3,143 | - | - |
| ISTH | 3,314 | - | 3,314 | - | - |
| Detect VTE Audit Study | 195,009 | - | 110,899 | - | 84,110 |
| **Total restricted funds** | 207,925 | 666 | 117,356 | - | 91,235 |
| **Unrestricted funds:** | | | | | |
| General Funds | 380,082 | 203,154 | 210,704 | - | 372,532 |
| **Total unrestricted funds** | 380,082 | 203,154 | 210,704 | - | 372,532 |

**Purpose of Restricted Funds**

Research – There was £666 donation received towards the Thrombosis UK Research Fund in the year (2025: £nil).

REGAIN Programme - The REGAIN Programme, launched by the charity in 2021, aims to address the psychological impact of Venous Thromboembolism (VTE), including complications associated with COVID-19. The initial development of the programme was funded by a restricted grant received in 2021, specifically allocated to support research and patient support activities relating to VTE and Vaccine-Induced Immune Thrombotic Thrombocytopenia (VITT). During the year, no further restricted income was received or expenditure incurred (2025: £12,960) in relation to the programme. The REGAIN Programme effectively closed on 31st January 2026.

**Purpose of Restricted Funds (.....Continued)**

VTE Grand Appeal – This campaign fund was launched in June 2018 to support, promote and inform research into VTE. The VTE Grand Appeal campaign closed on 31 December 2019. As at 31st January 2026, no additional income was received and expenditure totalling £3,143 incurred (2025: £nil) during the year. This fund has been fully utilised as at the year end.

ISTH – In 2023/24, Thrombosis UK received a restricted grant of approximately £28,500 (equivalent to $37,500) from the International Society on Thrombosis and Haemostasis (ISTH) to support the development of a Venous Thromboembolism (VTE) Patient Information App, designed to improve patient access to essential information about VTE. As at 31st January 2026, no additional income was received and expenditure totalling £3,314 incurred (2025: £10,755) during the year. This fund has been fully utilised as at the year end.

Detect VTE Audit Study - The Detect VTE Audit Study is a restricted fund established in 2024 to support research into the common barriers and underlying causes that can result in delays in the early diagnosis of venous thromboembolism (VTE). During the year ended 31st January 2024, Thrombosis UK secured educational research grants totalling £255,020 to initiate the study.

During the year, no additional income was received in respect of the research, but expenditure of £110,899 was incurred during the year in furtherance of the study, resulting in a closing restricted fund balance of £84,110 as at 31st January 2026.

**Purpose of Unrestricted Funds**

General funds balance includes:

(i) General - Thrombosis UK is committed to raising awareness and advancing thrombosis research in the UK. The Trustees have decided that as much as possible of the money donated by the general public will be used towards these objectives.

Events - Sponsorship fees received to enable the charity to widen the Public and Health Professionals' awareness of thrombosis and the related issues. The Charity did not receive any Sponsorship fees in the year.

**Transfers between funds**

There were no transfers between funds in the year.

**15) Capital Commitments**

There are no outstanding commitments as at 31 January 2026.

**16) Contingent Liabilities**

There are no contingent liabilities to report as at 31 January 2026.

**17) Post Balance Sheet Events**

There are no adjusting or non-adjusting events to report as at 31 January 2026.

**18) Trustee Remuneration**

The Trustees have not received any remuneration for their work as Trustees. Expenses totalling £157 (2025: £274) have been reimbursed to one Trustee.

## 19) Related Party Transactions

There were no Related Party Transactions in the year.

## 20) Taxation Status

The company being a registered charity (No.1090540) is not liable to Income and Corporation Taxes on its charitable activities.

## 21) Analysis of net assets between funds

| | Unrestricted Funds £ | Designated Funds £ | Restricted Funds £ | Total 2026 £ |
|---|---|---|---|---|
| Fixed assets | - | - | - | - |
| Cash and current Investments | 394,814 | - | 154,277 | 549,091 |
| Other current assets/(Liabilities) | (22,282) | - | (63,042) | (85,324) |
| Total | 372,532 | - | 91,235 | 463,767 |

| | Unrestricted Funds £ | Designated Funds £ | Restricted Funds £ | Total 2025 £ |
|---|---|---|---|---|
| Fixed assets | - | - | - | - |
| Cash and current Investments | 378,120 | - | 207,925 | 586,045 |
| Other current assets/(Liabilities) | 1,962 | - | - | 1,962 |
| Total | 380,082 | - | 207,925 | 588,007 |